Ticker brief
ROIV
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
7
authors 14d
5
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
daily mean sentiment, 2026-06-24 → 2026-07-01 · now -0.25 (−1 bearish … +1 bullish)
Who spoke5
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @Quantumup1 | C | -1.95 | 3 | +0.00 |
| @bullishchart | C | +1.98 | 1 | +0.25 |
| @PersimmonTI | A | -0.32 | 1 | +0.20 |
| @financespotnews | C | -0.87 | 1 | +0.35 |
| @CEOStockWatcher | C | · | 1 | -0.25 |
Recent signals7of 7 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-07-01 | @CEOStockWatcher | -0.25 | Director sold $56.44M of Roivant after stock rose 34%. | · | tweet ↗ |
| 2026-06-30 | @financespotnews | +0.35 | Roivant framed as biotech IPO-related play with M&A or partnership optionality. | · | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | William Blair and Wedbush reiterate bullish VRDN views; Wedbush raises PT to $43 from $32. | · | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | UBS reiterates VRDN Buy $50 after Lumvoa approval and outlines TAM and launch expectations. | · | tweet ↗ |
| 2026-06-29 | @Quantumup1 | +0.00 | Citizens reiterates VRDN Market Outperform $35 after FDA approval of Lumvoa. | · | tweet ↗ |
| 2026-06-28 | @PersimmonTI | +0.20 | ROIV CEO says pharma calls about IMVT all the time. | · | tweet ↗ |
| 2026-06-24 | @bullishchart | +0.25 | Lists bio/health stocks hitting or near fresh highs with prices. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.